Notable 52-Week Highs and Lows 11/8: (MCHP) (LSCC) (SNCR) High; (VRX) (CVS) (OMF) Low

November 8, 2016 3:39 PM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

52-Week High:
  • Microchip Technology (Nasdaq: MCHP) $65.61. Microchip Technology reported Q2 EPS of $0.94, versus the analyst estimate of $0.87. Revenue for the quarter came in at $871.4 million versus the consensus estimate of $860.96 million. Microchip Technology sees Q3 2017 EPS of $0.85 - $0.95, versus the consensus of $0.83. Microchip Technology sees Q3 2017 revenue of $821.4 - $873.8 million, versus the consensus of $844.58 million.

  • Lattice Semiconductor (Nasdaq: LSCC) $7.99. Lattice Semi reported Q3 EPS of $0.05, versus the analyst estimate of $0.06. Revenue for the quarter came in at $113.2 million versus the consensus estimate of $113.04 million.

  • Synchronoss Technologies (Nasdaq: SNCR) $46.23. Synchronoss Technologies reported Q3 EPS of $0.68, compared to the analyst estimate of $0.67. Revenue for the quarter came in at $181 million versus the consensus estimate of $177.83 million.

52-Week Low:
  • Valeant Pharma (NYSE: VRX) $13.77. Valeant Pharma reported Q3 EPS of $1.55, versus the analyst estimate of $1.75. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.49 billion. Valeant Pharma sees FY2016 EPS of $5.30 - $5.50, versus prior guidance of $6.60 - $7.00 and the consensus of $6.45. Valeant Pharma sees FY2016 revenue of $9.55 - $9.65 billion, versus prior guidance of $9.9 - $10.1 billion and the consensus of $9.92 billion.

  • CVS Health (NYSE: CVS) $69.30. CVS Health reported Q3 EPS of $1.64, which was $0.07 better than the analyst estimate of $1.57. Revenue for the quarter came in at $44.6 billion versus the consensus estimate of $45.29 billion. CVS Health sees FY2016 EPS of $5.77 - $5.83, versus prior guidance of $5.81 - $5.89 and the consensus of $5.85.

  • OneMain Holdings (NYSE: OMF) $16.56. OneMain Holdings reported Q3 EPS of $0.90, may not compare to the analyst estimate of $1.07.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Add Your Comment